Assignee
MEI PHARMA INC
US·28 granted patents·20 pending applications·147 citations·filing 2012–2023
Top patents by PatentIndex Score
48 records- 0198US9138478B2Substituted chroman derivatives, medicaments and use in therapyMEI PHARMA INC·Filed 2014·Granted Sep 22, 2015·13 cites·9 claims
- 0297US11723893B2Isoflavonoid compositions and methods for the treatment of cancerMEI PHARMA INC·Filed 2021·Granted Aug 15, 2023·5 cites·12 claims
- 0397US9381186B2Substituted chroman derivatives, medicaments and use in therapyMEI PHARMA INC·Filed 2015·Granted Jul 5, 2016·13 cites·6 claims
- 0497US9198895B2Chroman derivatives, medicaments and use in therapyMEI PHARMA INC·Filed 2015·Granted Dec 1, 2015·16 cites·10 claims
- 0597US8957109B2Chroman derivatives, medicaments and use in therapyMEI PHARMA INC·Filed 2013·Granted Feb 17, 2015·19 cites·19 claims
- 0696US10973799B2Isoflavonoid compositions and methods for the treatment of cancerMEI PHARMA INC·Filed 2019·Granted Apr 13, 2021·6 cites·9 claims
- 0795US9981936B2Isoflavonoid compositions and methods for the treatment of cancerMEI PHARMA INC·Filed 2017·Granted May 29, 2018·10 cites·14 claims
- 0894US11583514B2Isoflavonoid compounds and methods for the treatment of cancerMEI PHARMA INC·Filed 2020·Granted Feb 21, 2023·4 cites·8 claims
- 0994US10369132B2Isoflavonoid compositions and methods for the treatment of cancerMEI PHARMA INC·Filed 2018·Granted Aug 6, 2019·9 cites·15 claims
- 1092US10105346B2Isoflavonoid compounds and methods for the treatment of cancerMEI PHARMA INC·Filed 2017·Granted Oct 23, 2018·9 cites·8 claims
- 1191US11400097B2(Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseasesMEI PHARMA INC·Filed 2020·Granted Aug 2, 2022·2 cites·7 claims
- 1290US10335415B2(Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseasesMEI PHARMA INC·Filed 2018·Granted Jul 2, 2019·6 cites·21 claims
- 1390US10064868B2(Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseasesMEI PHARMA INC·Filed 2015·Granted Sep 4, 2018·7 cites·15 claims
- 1489US10603324B2(Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseasesMEI PHARMA INC·Filed 2019·Granted Mar 31, 2020·5 cites·19 claims
- 1588US11351176B2Combination therapyMEI PHARMA INC·Filed 2018·Granted Jun 7, 2022·4 cites·19 claims
- 1688US11304953B2Combination therapyMEI PHARMA INC·Filed 2018·Granted Apr 19, 2022·4 cites·19 claims
- 1784US9402829B2Benzimidazole derivatives: preparation and pharmaceutical applicationsMEI PHARMA INC·Filed 2015·Granted Aug 2, 2016·4 cites·8 claims
- 1883US12059422B2(Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseasesMEI PHARMA INC·Filed 2022·Granted Aug 13, 2024·0 cites·9 claims
- 1983US9717713B2Benzimidazole derivatives: preparation and pharmaceutical applicationsMEI PHARMA INC·Filed 2016·Granted Aug 1, 2017·3 cites·4 claims
- 2083US2023145478A1Isoflavonoid compounds and methods for the treatment of cancerMEI PHARMA INC·Filed 2023·Application pending·0 cites
- 2182US9024029B2Benzimidazole derivatives: preparation and pharmaceutical applicationsMEI PHARMA INC·Filed 2013·Granted May 5, 2015·4 cites·8 claims
- 2279US10980774B2Combination therapiesMEI PHARMA INC·Filed 2016·Granted Apr 20, 2021·2 cites·6 claims
- 2376US10201527B2Benzimidazole derivatives: preparation and pharmaceutical applicationsMEI PHARMA INC·Filed 2017·Granted Feb 12, 2019·1 cites·9 claims
- 2473US2016287555A1Substituted chroman derivatives, medicaments and use in therapyMEI PHARMA INC·Filed 2016·Application pending·0 cites
- 2572US12161644B2Combination therapyMEI PHARMA INC·Filed 2022·Granted Dec 10, 2024·0 cites·15 claims
- 2671US8901149B2Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applicationsMEI PHARMA INC·Filed 2014·Granted Dec 2, 2014·1 cites·10 claims
- 2770US10736881B2Benzimidazole derivatives: preparation and pharmaceutical applicationsMEI PHARMA INC·Filed 2018·Granted Aug 11, 2020·0 cites·16 claims
- 2869US2019142790A1Isoflavonoid compounds and methods for the treatment of cancerMEI PHARMA INC·Filed 2018·Application pending·0 cites
- 2967US2022265673A1Combination therapyMEI PHARMA INC·Filed 2022·Application pending·0 cites
- 3065US2016136129A1Chroman derivatives, medicaments and use in therapyMEI PHARMA INC·Filed 2015·Application pending·0 cites
- 3162US2025177409A1Combination therapy of pi3k inhibitor and pd-1 inhibitorMEI PHARMA INC·Filed 2023·Application pending·0 cites
- 3261US10626092B2Polymorphic forms of 3-[(2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide and uses thereofMEI PHARMA INC·Filed 2017·Granted Apr 21, 2020·0 cites·13 claims
- 3361US9266882B2Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applicationsMEI PHARMA INC·Filed 2014·Granted Feb 23, 2016·0 cites·11 claims
- 3460US2021100775A1Combination therapiesMEI PHARMA INC·Filed 2020·Application pending·0 cites
- 3557US2024197680A1Voruciclib dosing regimens and methods of treatment including the sameMEI PHARMA INC·Filed 2022·Application pending·0 cites
- 3655US2023233519A1Combination therapiesMEI PHARMA INC·Filed 2021·Application pending·0 cites
- 3755US2024016781A1Treatment of kras mutant cancersMEI PHARMA INC·Filed 2021·Application pending·0 cites
- 3855US2023129089A1Preparation of a 1,3,5-triazinyl benzimidazoleMEI PHARMA INC·Filed 2021·Application pending·0 cites
- 3952US2021196725A1Treatment of relapsed follicular lymphomaMEI PHARMA INC·Filed 2019·Application pending·0 cites
- 4052US2020317621A1Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ethyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereofMEI PHARMA INC·Filed 2020·Application pending·0 cites
- 4152US2021161909A1Combination therapyMEI PHARMA INC·Filed 2019·Application pending·0 cites
- 4251US12421216B2Voruciclib polymorphs and methods of making and using thereofMEI PHARMA INC·Filed 2020·Granted Sep 23, 2025·0 cites·17 claims
- 4350US2021000838A1Combination therapyMEI PHARMA INC·Filed 2019·Application pending·0 cites
- 4449US2015258068A1Combination therapiesMEI PHARMA INC·Filed 2013·Application pending·0 cites
- 4548US2022016082A1Combination therapies for high and very high risk mdsMEI PHARMA INC·Filed 2019·Application pending·0 cites
- 4645US2021299134A1Treatment of b cell malignanciesMEI PHARMA INC·Filed 2019·Application pending·0 cites
- 4745US2019201409A1Combination therapyMEI PHARMA INC·Filed 2017·Application pending·0 cites
- 4841US2014088102A1(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseasesMEI PHARMA INC·Filed 2012·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →